ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers

Abstract Context and objective To present a summary of the 2nd International Consultation on Bladder Cancer recommendations on the screening, diagnosis, and markers of bladder cancer using an evidence-based strategy. Evidence acquisition A detailed Medline analysis was performed for original article...

Full description

Saved in:
Bibliographic Details
Published in:European urology 2013-01, Vol.63 (1), p.4-15
Main Authors: Kamat, Ashish M, Hegarty, Paul K, Gee, Jason R, Clark, Peter E, Svatek, Robert S, Hegarty, Nicholas, Shariat, Shahrokh F, Xylinas, Evanguelos, Schmitz-Dräger, Bernd J, Lotan, Yair, Jenkins, Lawrence C, Droller, Michael, van Rhijn, Bas W, Karakiewicz, Pierre I
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - analysis
Biomarkers, Tumor - genetics
Bladder cancer
Cystoscopy - standards
Detection
Diagnosis
Diagnostic Techniques, Urological - standards
Humans
Markers
Mass Screening - methods
Mass Screening - standards
Neoplasm Recurrence, Local
Pathology, Molecular - standards
Predictive Value of Tests
Prognosis
Recommendations
Screening
Urinalysis - standards
Urinary Bladder Neoplasms - chemistry
Urinary Bladder Neoplasms - diagnosis
Urinary Bladder Neoplasms - genetics
Urinary Bladder Neoplasms - pathology
Urinary Bladder Neoplasms - therapy
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Context and objective To present a summary of the 2nd International Consultation on Bladder Cancer recommendations on the screening, diagnosis, and markers of bladder cancer using an evidence-based strategy. Evidence acquisition A detailed Medline analysis was performed for original articles addressing bladder cancer with regard to screening, diagnosis, markers, and pathology. Proceedings from the last 5 yr of major conferences were also searched. Evidence synthesis The major findings are presented in an evidence-based fashion. Large retrospective and prospective data were analyzed. Conclusions Cystoscopy alone is the most cost-effective method to detect recurrence of bladder cancer. White-light cystoscopy is the gold standard for evaluation of the lower urinary tract; however, technology like fluorescence-aided cystoscopy and narrow-band imaging can aid in improving evaluations. Urine cytology is useful for the diagnosis of high-grade tumor recurrence. Molecular medicine holds the promise that clinical outcomes will be improved by directing therapy toward the mechanisms and targets associated with the growth of an individual patient's tumor. The challenge remains to optimize measurement of these targets, evaluate the impact of such targets for therapeutic drug development, and translate molecular markers into the improved clinical management of bladder cancer patients. Physicians and researchers eventually will have a robust set of molecular markers to guide prevention, diagnosis, and treatment decisions for bladder cancer.
ISSN:0302-2838
1873-7560
DOI:10.1016/j.eururo.2012.09.057